Intra-Cellular Therapies Free Cash Flow 2013-2024 | ITCI

Intra-Cellular Therapies free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.

  • Intra-Cellular Therapies annual free cash flow for 2023 was $-0.124B, a 54.06% decline from 2022.
  • Intra-Cellular Therapies annual free cash flow for 2022 was $-0.271B, a 4.27% increase from 2021.
  • Intra-Cellular Therapies annual free cash flow for 2021 was $-0.26B, a 12.82% increase from 2020.

Intra-Cellular Therapies Free Cash Flow 2013-2024 | ITCI

  • Intra-Cellular Therapies annual free cash flow for 2023 was $-0.124B, a 54.06% decline from 2022.
  • Intra-Cellular Therapies annual free cash flow for 2022 was $-0.271B, a 4.27% increase from 2021.
  • Intra-Cellular Therapies annual free cash flow for 2021 was $-0.26B, a 12.82% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$139.4B
Bristol Myers Squibb (BMY)$115.2B
Gilead Sciences (GILD)$114.5B
Vertex Pharmaceuticals (VRTX)$104.5B
CSL (CSLLY)$84.4B
Regeneron Pharmaceuticals (REGN)$78.6B
GSK (GSK)$70.4B
Argenex SE (ARGX)$37.4B
Alnylam Pharmaceuticals (ALNY)$30.1B
BioNTech SE (BNTX)$27.6B
Biogen (BIIB)$21.9B
Illumina (ILMN)$20.8B
BeiGene (ONC)$18B
Moderna (MRNA)$16.2B
Genmab (GMAB)$13.9B
Incyte (INCY)$13.4B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.5B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.4B
Exact Sciences (EXAS)$10.5B
Vaxcyte (PCVX)$10.4B
QIAGEN (QGEN)$10.2B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.8B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8B
Jazz Pharmaceuticals (JAZZ)$7.5B